High-risk HPV infection of cervix
Conditions
Interventions
Experimental group:Proestrene combined with interferon group
Control group:Interferon group
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Age
40 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1: Patients with clinically confirmed postmenopausal high-risk cervical HPV infection requiring drug intervention 2: TCT or colposcopic biopsy results are negative or inflammatory 3: No contraindications to drug use 4: No history of estrogen or related medications in the three months prior to medication 5: Cooperate with follow-up, good compliance
Exclusion criteria
Exclusion criteria: 1: Unexplained vaginal bleeding 2: Known or suspected cervical precancerous lesions, cervical cancer and other cervical malignant lesions 3: Known or suspected estrogen-dependent diseases (such as uterine fibroids, adenomyopathy, adenomyoma, uterine sarcoma, etc.) 4: Contraindications to estrogen use 5: Suffer from bacterial, trichomoniasis, vulvovaginal candidiasis and other venereal diseases 6: Patients with severe systemic diseases of the liver, kidney, heart, hematopoietic system and nervous system, such as diabetes 7: Other drug use history is expected to affect the observation of drug efficacy 8: Patients who are unable to cooperate with collaborative examination and treatment 9: Patients whose disease progresses during treatment and cannot be treated conservatively 10: Patients with adverse reactions such as drug allergy during treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effectiveness of different drugs in the treatment of high-risk HPV infection after menopause; | — |
Secondary
| Measure | Time frame |
|---|---|
| Before and after TCT treatment;The vaginal environment (pH, H2O2, etc.) before and after treatment; | — |
Countries
China
Contacts
Public ContactGuo ruixia
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed